Plasma CCL2 upregulation in the peripheral blood (PB) and BM was reported in AML patients [35, 36], and CCL2 expression levels in the tumor microenvironment were elevated in MDS as well as AML [37]. This evidence concerns the gene CCL2 and myelodysplastic syndrome.